Oncternal Therapeutics Net Interest Income Over Time
| ONCT Stock | USD 0.75 0.04 5.63% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Oncternal Therapeutics Performance and Oncternal Therapeutics Correlation. Oncternal |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oncternal Therapeutics. If investors know Oncternal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oncternal Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (11.69) | Revenue Per Share 0.73 | Quarterly Revenue Growth 1.76 | Return On Assets (0.76) | Return On Equity (1.50) |
The market value of Oncternal Therapeutics is measured differently than its book value, which is the value of Oncternal that is recorded on the company's balance sheet. Investors also form their own opinion of Oncternal Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Oncternal Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oncternal Therapeutics' market value can be influenced by many factors that don't directly affect Oncternal Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Oncternal Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Oncternal Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oncternal Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Interest Income Analysis
Compare Oncternal Therapeutics and related stocks such as Neoleukin Therapeutics, CytomX Therapeutics, and Assembly Biosciences Net Interest Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CTMX | 736 K | 736 K | 736 K | 736 K | 736 K | 736 K | 736 K | 2.7 M | 7.6 M | 8.4 M | 1.8 M | 255 K | 1.7 M | 8.1 M | 4.3 M |
| ASMB | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 983.2 K | 3.1 M | 4.3 M | 2.6 M | 302 K | 1 M | 2.4 M | 1.6 M |
| TIL | 68 K | 68 K | 68 K | 68 K | 68 K | 68 K | 68 K | 68 K | 68 K | 68 K | 70 K | 3.8 M | 1.8 M | 4.5 M | 4.7 M |
| NUVB | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 3 M | 7.4 M | 24.6 M | 25.8 M |
| TARA | 466 K | 466 K | 466 K | 466 K | 466 K | 466 K | 466 K | 466 K | 466 K | 466 K | 466 K | 237 K | 1.1 M | 2.9 M | 3 M |
| VCNX | (3 M) | (3 M) | (3 M) | (3 M) | (3 M) | (3 M) | (3 M) | (1.4 M) | (392 K) | 0.0 | (489 K) | (809 K) | (2 K) | (1000) | (1.1 K) |
| MNPR | 7.2 K | 7.2 K | 7.2 K | 7.2 K | 7.2 K | 7.2 K | 7.2 K | 48.3 K | 103.2 K | 98.9 K | 81.9 K | 24 K | 21.2 K | 343.6 K | 360.8 K |
| SRZN | 91 K | 91 K | 91 K | 91 K | 91 K | 91 K | 91 K | 91 K | 91 K | 91 K | 91 K | 72 K | 781 K | 2.3 M | 2.4 M |
| PASG | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 696 K | 670 K | 343 K | 2.3 M | 2.6 M | 2.7 M |
| ABSI | (268 K) | (268 K) | (268 K) | (268 K) | (268 K) | (268 K) | (268 K) | (268 K) | (268 K) | (268 K) | (634 K) | (3.4 M) | (972 K) | (1.1 M) | (1.1 M) |
| ADVM | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| KZR | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 232 K | 1.6 M | 2.3 M | 1.2 M | 29 K | 2.9 M | 9.1 M | 9.5 M |
| ARMP | (835 K) | (835 K) | (835 K) | (835 K) | (835 K) | (835 K) | (835 K) | (835 K) | (835 K) | (835 K) | (600 K) | (59 K) | 29 K | (1.1 M) | (1.1 M) |
| KTTA | (508) | (508) | (508) | (508) | (508) | (508) | (508) | (508) | (508) | (508) | (508) | (508) | (102) | 242.4 K | 254.6 K |
| ADTX | (79.8 K) | (79.8 K) | (79.8 K) | (79.8 K) | (79.8 K) | (79.8 K) | (79.8 K) | (79.8 K) | (79.8 K) | (1.9 K) | (309.5 K) | (1.9 M) | (2.2 M) | (6.4 M) | (6.1 M) |
Oncternal Therapeutics and related stocks such as Neoleukin Therapeutics, CytomX Therapeutics, and Assembly Biosciences Net Interest Income description
The difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities.My Equities
My Current Equities and Potential Positions
| Oncternal Therapeutics | ONCT |
| Classification | Biotech |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 0.75
Additional Tools for Oncternal Stock Analysis
When running Oncternal Therapeutics' price analysis, check to measure Oncternal Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncternal Therapeutics is operating at the current time. Most of Oncternal Therapeutics' value examination focuses on studying past and present price action to predict the probability of Oncternal Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncternal Therapeutics' price. Additionally, you may evaluate how the addition of Oncternal Therapeutics to your portfolios can decrease your overall portfolio volatility.